Maggie Dempster

Preclinical development of monoclonal antibodies

Kathryn Chapman, Nick Pullen, Lee Coney et al. · mAbs · 2009 · 97 citations · Full text

Pharmacy, Immunology, Pharmaceutical Biotechnology +17

Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use

Fiona Sewell, Kathryn Chapman, Jessica A. Couch et al. · mAbs · 2017 · 30 citations · Full text

Pharmacy, Pharmaceutics, Pharmacology +17

Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach

Hsiao-Tzu Chien, Helen Prior, Laura Andrews et al. · Regulatory Toxicology and Pharmacology · 2022 · 29 citations · Full text

Pharmacy, Pharmacology, Toxicology +17

Nonclinical Aspects of Biopharmaceutical Development: Discussion of Case Studies at a PhRMA-FDA Workshop

Lorrene A. Buckley, K. A. Benson, Karen Davis‐Bruno et al. · International Journal of Toxicology · 2008 · 28 citations

Pharmacy, Pharmacology, Toxicology +17

Classic and evolving approaches to evaluating cross reactivity of mAb and mAb-like molecules – A survey of industry 2008–2019

Timothy K. MacLachlan, Shari A. Price, Joy Cavagnaro et al. · Regulatory Toxicology and Pharmacology · 2021 · 12 citations

Pharmacy, Molecular Biology, Antibody Engineering +12